Cholestanol metabolism in patients with cerebrotendinous xanthomatosis: Absorption, turnover, and tissue deposition

Journal of Lipid Research

Volumn 48, Issue 1, 2007, Pages 185-192

  Bhattacharyya, Ashim K ^a   Lin, Don S ^b   Connor, William E ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

27 hydoxy cholesterol; 7 hydroxy 4 cholesten 3 one; Blood brain barrier; Brain cholestanol; Brain sterols; Chenodeoxycholic acid; Cholesterol and cholestanol turnover; Neurological disorders; Sterol 27 hydroxylase

Indexed keywords

CHOLESTANOL; LIPID;

ABSORPTION; ADULT; ARTICLE; BLOOD BRAIN BARRIER; CASE REPORT; CEREBROTENDINOUS XANTHOMATOSIS; ERYTHROCYTE; HUMAN; LIPID BLOOD LEVEL; MALE; NERVE BIOPSY; NERVOUS TISSUE; PRIORITY JOURNAL; PSOAS MUSCLE; STEROL ANALYSIS;

CARBON RADIOISOTOPES; CHOLESTANOL; CHOLESTEROL; ERYTHROCYTES; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; REFERENCE VALUES; TISSUE DISTRIBUTION; XANTHOMATOSIS, CEREBROTENDINOUS;

EID: 33845975239     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M600113-JLR200     Document Type: Article

References (36)

1. van Bogaert, L., H. J. Scherer, and E. Epstein. 1937. Une Forme Cerebrale de la Cholesterinose Generalisee. Masson et Cie, Paris.
2. th edition. J. B. Stanbury, J. B. Wyngaarden, and D. S. Fredrickson, editors. McGraw-Hill, New York. 656-669.
3. th edition. J. B. Stanbury, J. B. Wyngaarden, D. S. Fredrickson, J. L. Goldstein, and M. S. Brown, editors. McGraw-Hill, New York. 713-730.
4. th edition. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 1283-1302.
5. Skrede, S., I. Bjorkhem, E. A. Kvittingen, M. S. Buchmann, S. O. Lio, C. East, and S. Grundy. 1986. Demonstration of 26-hydroxylation of C27-steroids in human skin fibroblasts and a deficiency of its activity in cerebrotendinous xanthomatosis. J. Clin. Invest. 78: 729-735.
6. th Edition. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 2961-2988.
7. Cali, J. J., C-L. Hsieh, U. Francke, and D. W. Russell. 1991. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J. Biol. Chem. 266: 7779-7783.
8. Leitersdorf, E., A. Reshef, V. Meiner, R. Levitzki, S. P. Schwartz, E. J. Dann, N. Berkman, J. J. Cali, L. Klapholz, and V. M. Berginer. 1993. Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews of Moroccan origin. J. Clin. Invest. 91: 2488-2496.
9. Nakashima, N., Y. Sakai, H. Sakai, T. Yanase, M. Haji, F. Umeda, S. Koga, T. Hoshita, and H. Nawata. 1994. A point mutation in the bile acid biosynthetic enzyme sterol 27-hydroxylase in a family with cerebrotendinous xanthomatosis. J. Lipid Res. 35: 663-668.
10. Kim, K-S., S. Kubota, M. Kuroyama, J. Fujiyama, I. Bjorkhem, G. Eggertsen, and Y. Seyama. 1994. Identification of new mutations in sterol 27-hydroxylase gene in Japanese patients with cerebrotendinous xanthomatosis. J. Lipid Res. 35: 1031-1039.
11. Lee, M. H., S. Hazard, J. D. Carpten, S. Yi, J. Cohen, G. T. Gerhardt, G. Salen, and S. B. Patel. 2001. Fine-mapping, mutation analyses and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees. J. Lipid Res. 42: 159-169.
12. Miettinen, T. A., E. H. Ahrens, Jr., and S. M. Grundy. 1965. Quantitative isolation and gas-liquid chromatographic analysis of total dietary and fecal neutral steroids. J. Lipid Res. 6: 411-424.
13. Connor, W. E., and D. S. Lin. 1974. The intestinal absorption of dietary cholesterol by hypercholesterolemic (type II) and normocholesterolemic humans. J. Clin. Invest. 53: 1062-1077.
14. Bhattacharyya, A. K., W. E. Connor, and A. A. Spector. 1976. Abnormalities of cholesterol turnover in hypercholesterolemic (type II) patients. J. Lab. Clin. Med. 88: 202-214.
15. Goodman, D. S., and R. P. Noble. 1968. Turnover of plasma cholesterol in man. J. Clin. Invest. 47: 231-241.
16. Abell, L. L., B. B. Levy, B. B. Brodie, and F. E. Kendall. 1952. A simplified method for the estimation of total cholesterol in serum and determination of its specificity. J. Biol. Chem. 195: 357-366.
17. Rose, H. G., and M. Oklander. 1965. Improved procedure for the extraction of lipids from human erythrocytes. J. Lipid Res. 6: 428-431.
18. Bhattacharyya, A. K., W. E. Connor, F. A. Mousoif, and A. E. Flatt. 1976. Turnover of xanthoma cholesterol in hyperlipoproteinemia patients. J. Lab. Clin. Med. 87: 503-518.
19. Neuwelt, E. A., editor. 1989. Implications of the Blood Brain Barrier and Its Manipulation. Vol. 1. Basic Science Aspects. Plenum Press, New York.
20. Menkes, J. H., J. R. Schimschock, and P. D. Swanson. 1968. Cerebrotendinous xanthomatosis: the storage of cholestanol within the nervous system. Arch. Neurol. 19: 47-53.
21. Salen, G. 1971. Cholestanol deposition in cerebrotendinous xanthomatosis. Ann. Intern. Med. 76: 843-851.
22. Philippart, M., and M. L. van Bogeart. 1969. Cholestanotosis (cerebrotendinous xanthomatosis): a follow-up study on the original family. Arch. Neurol. 21: 603-610.
23. Salen, G., V. Berginer, V. Shore, I. Horak, E. Horak, G. S. Tint, and S. Shefer. 1987. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid. N. Engl. J. Med. 316: 1233-1238.
24. Norlin, M., S. von Bahr, I. Bjorkehm, and K. Wikvall. 2003. On the substrate specificity of human CYP27A1: implications for bile acid and cholestanol formation. J. Lipid Res. 44: 1515-1522.
25. Gardner-Medwin, D., Y. Kishimoto, B. M. Derby, and H. W. Moser. 1971. Cerebrotendinous xanthomatosis: in vivo labeling of cerebral sterols and sterol esters. Trans. Am. Neurol. Assoc. 96: 241-244.
26. Derby, B. M., S. Pogacar, C. Muckenhausen, H. W. Moser, and E. P. Richardson. 1970. Cerebrotendinous xanthomatosis: a clinicopathological, biochemical, and metabolic study (Abstract). J. Neuropathol. Exp. Neurol. 29: 139.
27. Bjorkhem, I. 1992. Mechanism of degradation of the steroid side chain in the formation of bile acids. J. Lipid Res. 33: 455-471.
28. Shore, V., G. Salen, F. W. Cheng, T. Forte, S. Shefer, G. S. Tint, and F. Lindgren. 1981. Abnormal high density lipoproteins in cerebrotendinous xanthomatosis. J. Clin. Invest. 68: 1295-1304.
29. Chiang, J. Y. L. 2002. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr. Rev. 23: 443-463.
30. Mano, N., Y. Sato, M. Nagata, T. Goto, and J. Goto. 2004. Biosynthesis of 3β-hydroxy-5-cholenoic acid into chenodeoxycholic acid by rat brain enzyme systems. J. Lipid Res. 45: 1741-1748.
31. Nariyasu, M., T. Goto, M. Uchida, K. Nishimura, M. Ando, N. Kobayashi, and J. Goto. 2004. Presence of protein-bound unconjugated bile acids in the cytoplasmic fraction of rat brain. J. Lipid Res. 45: 295-300.
32. Zhang, J., Y. Akwa, M. El-Etr, E. E. Baulieu, and J. Sjovall. 1997. Metabolism of 27-, 25- and 24-hydroxycholesterol in rat glial cells and neurons. Biochem. J. 322: 175-184.
33. Salen, G., and S. M. Grundy. 1973. The metabolism of cholestanol, cholesterol and bile acids in cerebrotendinous xanthomatosis. J. Clin. Invest. 52: 2822-2835.
34. Bürger, M., and W. Wintersteel. 1931. Das Schicksal peroral verabreichten Cholesterins und Koprosterins im menschlichen Darm Zeitschrift fur physiologische Chemie. Z. Physiol. Chem. 202: 237-245.
35. Dam, H. 1934. The formation of coprosterol in the intestine. I. Possible role of dihydroxycholesterol, and a method of determining dihydroxycholesterol in presence of coprosterol. Biochem. J. 28: 815-819.
36. Stahl, W. L., S. M. Sumi, and P. D. Swanson. 1971. Subcellular distribution of cerebral cholestanol in cerebrotendinous xanthomatosis. J. Neurochem. 18: 403-413.